The drugmaker said on Friday it plans to spend more than 1.2 billion euros ($1.26 billion) to expand its Puurs, Belgium, ...

AMRX is expanding into GLP-1 manufacturing and biosimilars, using partnerships and acquisitions to strengthen its higher-value product strategy.

You're currently following this author! Want to unfollow? Unsubscribe via the link in your email. Albert Bourla, Pfizer's CEO, said on Monday that the company may move overseas drug manufacturing back ...

Pfizer PFE has committed significant resources toward the development of treatments in the fields of oncology, metabolic ...

Pfizer’s latest share move reflects renewed attention on its label expansion, research pipeline, dividend profile, and ...

Pfizer CEO Albert Bourla on Tuesday said uncertainty around President Donald Trump’s planned pharmaceutical tariffs is deterring the company from further investing in U.S. manufacturing and research ...

AbbVie and Pfizer chart distinct paths in revenue growth, risk, and valuation. Explore how their financials and strategies stack up for investors this year.

With a market cap of $149.2 billion, Pfizer Inc. (PFE) is a global biopharmaceutical company that discovers, develops, ...

Drugmaker Pfizer has agreed to lower drug costs and invest $70 billion in U.S. manufacturing under a deal struck with the Trump administration, President Donald Trump said Tuesday.The announcement, ...

With U.S. syphilis cases on the rise and Pfizer’s Bicillin treatment still in short supply, France’s Laboratoires Delbert is stepping in to help with temporary imports. The French drugmaker is working ...